BizenCell Receives Approval for Phase 1 Clinical Trial of Acute Myeloid Leukemia Treatment

[Asia Economy Reporter Hyun-ui Cho] VigenCell, a company specializing in the development of immune cell therapies, announced on the 24th that it has received approval from the Ministry of Food and Drug Safety for the Phase 1 clinical trial of the acute myeloid leukemia immune cell therapy ‘VT-Tri(1)-A’.

VT-Tri(1)-A is a new drug pipeline developing a patient-customized tumor antigen-targeted cytotoxic T cell therapy using T cells. It is being developed for acute myeloid leukemia based on VigenCell’s platform technology, V-Tier.

The Phase 1 clinical trial will evaluate safety, tolerability, and pharmacodynamics after administration to patients with refractory acute myeloid leukemia, and will be conducted at Seoul St. Mary’s Hospital. VigenCell plans to start the clinical trial within this year and secure Phase 1 clinical trial results by 2022.

Meanwhile, VigenCell began full-scale listing procedures last April by selecting Daishin Securities and KB Securities as underwriters for its initial public offering. The company plans to apply for a technology evaluation in December with the goal of a technology-specialized listing next year.